Form 4: Elanco Animal Health CEO Acquires Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired 229.6219 deferred stock units on December 27, 2024, convertible to common stock or cash.

Summary

• Jeffrey N. Simmons, the President, CEO, and Director of Elanco Animal Health Inc., acquired 229.6219 deferred stock units on December 27, 2024.
• These deferred stock units represent the right to receive one share of Elanco common stock or the cash equivalent.
• The units will settle in cash or shares of common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.
• Following this transaction, Mr. Simmons directly owns 4,992.5338 shares of Elanco common stock.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it reports a standard transaction of deferred stock units. It is neither particularly positive nor negative.

Positives

• The acquisition of deferred stock units by the CEO could be seen as a positive sign of confidence in the company's future performance.

Future Outlook

The deferred stock units will settle in cash or shares of common stock following termination of employment or during a specified future year.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who have made transactions in their company's stock. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• Similar filings are common across publicly traded companies, particularly when executives receive stock-based compensation.
• The use of deferred stock units is a typical method for aligning executive interests with long-term shareholder value, and is a common practice in the pharmaceutical and animal health industries.
• Comparable companies such as Zoetis and IDEXX Laboratories also regularly report similar insider transactions.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates the CEO's continued investment in the company.

Key Dates

Keywords

Elanco Animal Health, deferred stock units, insider trading, executive compensation, Jeffrey N. Simmons, stock ownership